Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (3655)	5/28/1998 2:51:00 PM
From: barbara sperino	Read Replies (1) \| Respond to of 25711

IMDS I'm in. News just hit the wires. Hey unless you have had to have Mammogram they way they do it now. Might not realize what a great advancement this will be. Besides has a female ceo so it can't lose. (COMTEX) IMAGING DIAGNOSTIC SYSTEMS, INC. RECEIVES $15 MILLION EQUITY IMAGING DIAGNOSTIC SYSTEMS, INC. RECEIVES $15 MILLION EQUITY LINE OF CREDIT FORT LAUDERDALE, Fla., May 28 /PRNewswire/ -- Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS) announced today that it has entered into an irrevocable agreement with a consortium of prominent European banking institutions who will invest up to $15 million in the Company over the next three years. Imaging Diagnostic Systems President, Ms. Linda Grable, said, "The completion of this financing, which is structured as an equity line of credit, is significant because it provides the key capital component for our completing FDA clinical trials through PMA submission and subsequently ramping up to full manufacturing capacity. With no future financial concerns facing us, we are now free to focus strictly on bringing the world's first laser-based mammography system to market. It is indeed an exciting time for Imaging Diagnostics and our valued shareholders, whose patience and support have been truly appreciated." The Company is currently conducting in-house clinical studies monitored by an Institutional Review Board (IRB) of approximately fifteen to twenty patients whose studies will establish image interpretation criteria for PMA submission. Upon completion of the first phase clinical studies, the Company will commence the second phase clinical trials at three prominent hospitals. The Company will launch manufacturing of its CT Laser Mammography (CTLM(TM)) Systems immediately following the first phase clinical trials to ensure timely delivery of systems to the Company's European customers. Imaging Diagnostic Systems has developed the world's first patented laser- based mammography system that utilizes state-of-the-art laser technology and proprietary computed algorithms that create contiguous cross sectional slices of the breast. This procedure is performed without the use of x-rays and/or painful breast compression. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to, risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, regulator approval processes, and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. SOURCE Imaging Diagnostic Systems, Inc. -0- 05/28/98 /CONTACT: Deborah O'Brien, Imaging Diagnostic Systems, Inc., 954-581-9800; Public Relations contact: Margie Adelman, TransMedia Consultants, 561-998-4888/ (IMDS) CO: Imaging Diagnostic Systems, Inc. ST: Florida IN: MTC SU: * end of story *

To: Joe Copia who wrote (3655)	5/28/1998 2:52:00 PM
From: Joe Copia	Respond to of 25711

Thursday May 28, 2:28 pm Eastern Time Company Press Release SOURCE: Imaging Diagnostic Systems, Inc. Imaging Diagnostic Systems, Inc. Receives $15 Million Equity Line Of Credit FORT LAUDERDALE, Fla., May 28 /PRNewswire/ -- Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS - news) announced today that it has entered into an irrevocable agreement with a consortium of prominent European banking institutions who will invest up to $15 million in the Company over the next three years. Imaging Diagnostic Systems President, Ms. Linda Grable, said, ''The completion of this financing, which is structured as an equity line of credit, is significant because it provides the key capital component for our completing FDA clinical trials through PMA submission and subsequently ramping up to full manufacturing capacity. With no future financial concerns facing us, we are now free to focus strictly on bringing the world's first laser-based mammography system to market. It is indeed an exciting time for Imaging Diagnostics and our valued shareholders, whose patience and support have been truly appreciated.'' The Company is currently conducting in-house clinical studies monitored by an Institutional Review Board (IRB) of approximately fifteen to twenty patients whose studies will establish image interpretation criteria for PMA submission. Upon completion of the first phase clinical studies, the Company will commence the second phase clinical trials at three prominent hospitals. The Company will launch manufacturing of its CT Laser Mammography (CTLM(TM)) Systems immediately following the first phase clinical trials to ensure timely delivery of systems to the Company's European customers. Imaging Diagnostic Systems has developed the world's first patented laser- based mammography system that utilizes state-of-the-art laser technology and proprietary computed algorithms that create contiguous cross sectional slices of the breast. This procedure is performed without the use of x-rays and/or painful breast compression. Joe PTG&LI !!! allstocks.com